Literature DB >> 21477166

Declined guideline adherence in older breast cancer patients: a population-based study in the Netherlands.

Ines Weggelaar1, Katja K Aben, Michiel C Warlé, Luc J Strobbe, Dick Johan van Spronsen.   

Abstract

Older women with primary operable breast cancer might receive suboptimal care due to their advanced age. Although several studies reported age as an independent determinant for receiving none or less treatment according to accepted standards, prospective data are lacking. This study evaluates the adherence to a consensus protocol in unselected women aged 80 years and older in the Netherlands. Data were derived from the Dutch population-based Cancer Registry held by the Comprehensive Cancer Centre East. In this study all female patients, 60 years and older, diagnosed with breast cancer TNM stage I-IIIa in the period 2001 until 2006 were selected. Applied treatment according to the Dutch guideline was compared for different age groups. Differences between age groups were evaluated using a chi-square test. In total, 2336 breast cancer patients were studied. Treatment adherence was significantly lower for surgery, radiation therapy and systemic therapy in women aged 80 years and older, and all modalities were applied much less frequently, except for endocrine therapy which was more frequently applied in the oldest old. This study shows a sharp decline in guideline adherence for unselected women aged 80 years and older with primary operable breast cancer, with an observed shift from appropriate locoregional treatment toward endocrine therapy. Whether this approach is justified or not should preferably be tested prospectively.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21477166     DOI: 10.1111/j.1524-4741.2011.01074.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  8 in total

Review 1.  How to implement a geriatric assessment in your clinical practice.

Authors:  Schroder Sattar; Shabbir M H Alibhai; Hans Wildiers; Martine T E Puts
Journal:  Oncologist       Date:  2014-09-03

2.  Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology.

Authors:  E C Inwald; O Ortmann; M Koller; F Zeman; F Hofstädter; M Evert; G Brockhoff; M Klinkhammer-Schalke
Journal:  Breast Cancer Res Treat       Date:  2017-02-15       Impact factor: 4.872

3.  Undertreated breast cancer in the elderly.

Authors:  Manmeet Kaur Malik; Paul Ian Tartter; Rachel Belfer
Journal:  J Cancer Epidemiol       Date:  2013-01-10

4.  Population-based study of breast cancer in older women: prognostic factors of relative survival and predictors of treatment.

Authors:  Pegdwende Olivia Dialla; Tienhan Sandrine Dabakuyo; Sophie Marilier; Julie Gentil; Patrick Roignot; Ariane Darut-Jouve; Marie-Laure Poillot; Valérie Quipourt; Patrick Arveux
Journal:  BMC Cancer       Date:  2012-10-15       Impact factor: 4.430

5.  Undertreatment of breast cancer in the elderly.

Authors:  Nicola Rocco; Corrado Rispoli; Gennaro Pagano; Silvio Ascione; Rita Compagna; Michele Danzi; Antonello Accurso; Bruno Amato
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

6.  Surgical treatment of breast cancer in patients aged 80 years or older--how much is enough?

Authors:  Nikola Besic; Hana Besic; Barbara Peric; Gasper Pilko; Rok Petric; Jan Zmuc; Radan Dzodic; Andraz Perhavec
Journal:  BMC Cancer       Date:  2014-09-23       Impact factor: 4.430

7.  Provision of breast cancer care and survival in Germany - results from a population-based high resolution study from Saarland.

Authors:  Bernd Holleczek; Hermann Brenner
Journal:  BMC Cancer       Date:  2014-10-10       Impact factor: 4.430

8.  Healthcare providers' adherence to breast cancer guidelines in Europe: a systematic literature review.

Authors:  Ena Niño de Guzmán; Yang Song; Pablo Alonso-Coello; Carlos Canelo-Aybar; Luciana Neamtiu; Elena Parmelli; Javier Pérez-Bracchiglione; Montserrat Rabassa; David Rigau; Zuleika Saz Parkinson; Iván Solà; Adrián Vásquez-Mejía; Ignacio Ricci-Cabello
Journal:  Breast Cancer Res Treat       Date:  2020-05-06       Impact factor: 4.872

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.